CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 60 target
Drug / intervention
MSCs +2 morebiological
Likely dose
AZM 0.25gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02543073
NCT02543073Phase 2Unknown
CompareCT.gov

Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation

Nanfang Hospital, Southern Medical University·interventional·Posted Sep 7, 2015·Updated May 10, 2017

In Brief

A Phase 2 clinical trial evaluating MSCs, AZM, and 1 other intervention for Lung Diseases, Interstitial and 2 related conditions. Targeting 60 participants across 1 site.

Detailed Summary

Interstitial lung disease (ILD） is the late pulmonary complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) leading to high morbidity and mortality. At present, the treatment for ILD after allo-HSCT remains in discussion. In this study, the efficacy of mesenchymal stem cells (MSCs) combined azithromycin as well as glucocorticoid as the treatment of ILD will be evaluated in the recipients of allo-HSCT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Diseases, Interstitial, Hematopoietic Stem Cell Transplantation, Bronchiolitis Obliterans
CountriesChina
CollaboratorsSun Yat-sen University

Timeline

Phase 2UnknownOverdue
201520162017201820192020202120222023202420252026
First PostedSep 7, 2015
Enrollment StartSep 1, 2014
Primary CompletionDec 1, 2017
Study CompletionJun 1, 2018
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 10.8 years ago

Interventions

MSCsbiological

MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.

AZMdrug

AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.

Glucocorticoiddrug

Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.